Abstract
Background: Lung cancer is the main cause of brain metastasis, primary lesions in patients with brain metastases from lung cancer are most often treated with surgery, and adjuvant chemoradiotherapy and other therapeutic methods are used to control disease progression based on the characteristics of the primary lesions. Materials and methods: Here, we report a case of a patient with NSCLC who received brigatinib treatment for the primary lung lesions after the resection of brain metastases based on the ALK gene rearrangement detected in the resected brain metastases by highthroughput sequencing. Results: The result of ten months follow-up showed satisfactory curative effect. The primary lung lesions disappeared and no sign of recurrence in the brain and lung Conclusion: This method provides a new option for the treatment of primary lung lesions in patients with brain metastases from lung cancer Keywords: NSCLC; Brain metastasis; ALK gene rearrangement; Brigatinib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Clinical Images and Medical Case Reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
